💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

UPDATE 1-Reckitt Benckiser to buy India's Paras Pharma

Published 12/12/2010, 09:44 PM
Updated 12/12/2010, 09:48 PM

* To pay 32.6 bln rupees, or $726 mln

* PE firm Actis owns 63 pct of Paras

* Other owners include Sequoia Capital, founder Patel

NEW YORK, Dec 12 (Reuters) - British consumer goods company Reckitt Benckiser said on Sunday it agreed to buy privately-held Indian firm Paras Pharmaceuticals for 32.6 billion rupees ($726 million).

Paras, which is expected to clock sales of more than 1 million rupees in 2010, makes several over-the-counter medications, including Moov pain relief ointment, Krack heel care lotion, and D'Cold cold remedy.

Private equity firm Actis, which owns 63 percent of Paras, and the firm's other shareholders have agreed to sell theior stakes in the company. Paras' other shareholders include Sequoia Capital, Paras founder Girish Patel and his family.

In October, India's Business Standard newspaper reported that GlaxoSmithKline Plc , Sanofi-Aventis , Novartis AG and U.S.-based Johnson & Johnson had submitted concrete bids to acquire majority stake in Paras.

It reported that Japan's Taisho Pharmaceutical had also been expected to join the race.

Reckitt Benckiser was advised by JP Morgan on the deal. Actis and the other Paras shareholders were advised by Morgan Stanley . (Reporting by Michael Erman; Editing by Anshuman Daga)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.